Deflazacort carries the risks common to all [[corticosteroids]], including [[immune suppression]], decreased [[bone density]], and [[endocrine]] insufficiency. In clinical trials, the most common side effects (>10% above placebo) were [[Cushing's]]-like appearance, weight gain, and increased appetite.<ref>http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf</ref>

 

